International Cooperation on Harmonisation of Technical Requirements for Registration of Veterinary Medicinal Products; Final Guidance for Industry on “Specifications: Test Procedures and Acceptance Criteria for New Veterinary Drug Substances and New Medicinal Products: Chemical Substances;” Availability, 34625-34626 [E6-9327]

Download as PDF Federal Register / Vol. 71, No. 115 / Thursday, June 15, 2006 / Notices DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration [Docket No. 2005D–0199] International Cooperation on Harmonisation of Technical Requirements for Registration of Veterinary Medicinal Products; Final Guidance for Industry on ‘‘Specifications: Test Procedures and Acceptance Criteria for New Veterinary Drug Substances and New Medicinal Products: Chemical Substances;’’ Availability AGENCY: Food and Drug Administration, HHS. jlentini on PROD1PC65 with NOTICES ACTION: Notice of availability. SUMMARY: The Food and Drug Administration (FDA) is announcing the availability of a guidance document for industry (#176) entitled ‘‘Specifications: Test Procedures and Acceptance Criteria for New Veterinary Drug Substances and New Medicinal Products: Chemical Substances’’ (VICH GL–39). This guidance has been developed for veterinary use by the International Cooperation on Harmonization of Technical Requirements for Registration of Veterinary Medicinal Products (VICH). This VICH guidance document is intended to assist to the extent possible, in the establishment of a single set of recommended global specifications for new veterinary drug substances and medicinal products. It provides guidance through recommendations on the setting and justification of acceptance criteria and the selection of test procedures for new veterinary drug substances of synthetic chemical origin, and new medicinal products produced from them, which have not been registered previously in the United States, the European Union, or Japan. DATES: Submit written or electronic comments at any time. ADDRESSES: Submit written requests for single copies of the guidance to the Communications Staff (HFV–12), Center for Veterinary Medicine (CVM), Food and Drug Administration, 7519 Standish Pl., Rockville, MD 20855. Send one selfaddressed adhesive label to assist that office in processing your requests. See the SUPPLEMENTARY INFORMATION section for electronic access to the guidance document. Submit written comments on the guidance to the Division of Dockets Management (HFA–305), Food and Drug Administration, 5630 Fishers Lane, rm. 1061, Rockville, MD 20852. Submit VerDate Aug<31>2005 15:47 Jun 14, 2006 Jkt 208001 34625 electronic comments to https:// www.fda.gov/dockets/ecomments. Comments should be identified with the full title of the guidance and the docket number found in brackets in the heading of this document. FOR FURTHER INFORMATION CONTACT: Dennis Bensley, Center for Veterinary Medicine (HFV–143), Food and Drug Administration, 7500 Standish Pl., Rockville, MD 20855, 301–827–6956, email: dennis.bensley@fda.hhs.gov. SUPPLEMENTARY INFORMATION: Australia/New Zealand, one representative from the government of Canada, and one representative from the industry of Canada. The VICH Secretariat, which coordinates the preparation of documentation, is provided by the International Federation for Animal Health (IFAH). An IFAH representative also participates in the VICH Steering Committee meetings. I. Background In the Federal Register of May 27, 2005 (70 FR 30761), FDA published the notice of availability of the VICH draft guidance, giving interested persons until June 27, 2005, to submit comments. No comments were received. At a meeting held on November 2005, the VICH Steering Committee endorsed the final guidance for industry, (VICH GL–39). This VICH guidance addresses specifications, i.e., those tests, procedures, and acceptance criteria which play a major role in assuring the quality of the new veterinary drug substance and medicinal product at release and during shelf life. In recent years, many important initiatives have been undertaken by regulatory authorities and industry associations to promote the international harmonization of regulatory requirements. FDA has participated in efforts to enhance harmonization and has expressed its commitment to seek scientifically based harmonized technical procedures for the development of pharmaceutical products. One of the goals of harmonization is to identify and then reduce differences in technical requirements for drug development among regulatory agencies in different countries. FDA has actively participated in the International Conference on Harmonization of Technical Requirements for Approval of Pharmaceuticals for Human Use for several years to develop harmonized technical requirements for the approval of human pharmaceutical and biological products among the European Union, Japan, and the United States. The VICH is a parallel initiative for veterinary medicinal products. The VICH is concerned with developing harmonized technical requirements for the approval of veterinary medicinal products in the European Union, Japan, and the United States, and includes input from both regulatory and industry representatives. The VICH Steering Committee is composed of member representatives from the European Commission, European Medicines Evaluation Agency, European Federation of Animal Health, Committee on Veterinary Medicinal Products, the U.S. FDA, the U.S. Department of Agriculture, the Animal Health Institute, the Japanese Veterinary Pharmaceutical Association, the Japanese Association of Veterinary Biologics, and the Japanese Ministry of Agriculture, Forestry and Fisheries. Four observers are eligible to participate in the VICH Steering Committee: One representative from the government of Australia/New Zealand, one representative from the industry in PO 00000 Frm 00037 Fmt 4703 Sfmt 4703 II. Guidance on Chemical Substance III. Paperwork Reduction Act of 1995 This guidance document refers to previously approved collections of information found in FDA regulations. These collections of information are subject to review by the Office of Management and Budget (OMB) under the Paperwork Reduction Act of 1995 (44 U.S.C. 3501–3520). The collections of information in 21 CFR 514.1 have been approved under OMB Control No. 0910–0032 (expiration date 12/31/2007). IV. Significance of Guidance This document, developed under the VICH process, has been revised to conform to FDA’s good guidance practices regulation (21 CFR 10.115). For example, the document has been designated ‘‘guidance’’ rather than ‘‘guideline.’’ In addition, guidance documents must not include mandatory language such as ‘‘shall,’’ ‘‘must,’’ ‘‘require,’’ or ‘‘requirement,’’ unless FDA is using these words to describe a statutory or regulatory requirement. The VICH guidance (#176) is consistent with the agency’s current thinking on the new veterinary drug substances and medicinal products. This guidance does not create or confer any rights for or on any person and will not operate to bind FDA or the public. An alternative method may be used as long as it satisfies the requirements of applicable statutes and regulations. E:\FR\FM\15JNN1.SGM 15JNN1 34626 Federal Register / Vol. 71, No. 115 / Thursday, June 15, 2006 / Notices V. Comments As with all of FDA’s guidances, the public is encouraged to submit written or electronic comments pertinent to this guidance. FDA will periodically review the comments in the docket and, where appropriate, will amend the guidance. The agency will notify the public of any such amendments through a notice in the Federal Register. Interested persons may submit to the Division of Dockets Management (see ADDRESSES) written or electronic comments regarding this document. Submit a single copy of electronic comments or two paper copies of any mailed comments, except that individuals may submit one paper copy. Comments are to be identified with the docket number found in brackets in the heading of this document. Received comments may be seen in the Division of Dockets Management between 9 a.m. and 4 p.m., Monday through Friday publication, shall become effective June 15, 2006. CATEGORIES OF INDIVIDUALS COVERED BY THE SYSTEM: Contact Stephen Heath, MD, IHS Risk Management Consultant, Albuquerque Indian Health Center, 801 Vassar Drive, NE., Albuquerque, New Mexico 87106 or via the Internet at Stephen.Heath@ihs.qov. Prospective, current and former IHS medical staff members. The term IHS medical staff includes fully licensed individuals permitted by law to provide patient care services independently and without concurrent professional direction or supervision, within the scope of his/her license and in accordance with individually granted clinical privileges. The IHS medical staff includes physicians (M.D. and D.O.) and dentists and may include other health care practitioners such as psychologists, optometrists, podiatrists, audiologists, and, in some states, certified nurse midwives. Types of assignment categories of current and former IHS medical staff members include the following: Provisional—Those new members of the medical staff who are serving a required initial probationary period, as specified in the local medical staff bylaws. During this time, their qualifications for membership on the active or courtesy IHS medical staff are assessed. Active—Those members who are Federal employees and/or spend at least fifty percent of their professional time providing patient care related services in the facility. Temporary—Those members who provide services on a short-term basis or have applied for active medical staff membership and are awaiting a full credential review. Courtesy or Associate—Those members who generally provide services on a periodic or episodic basis (e.g., consultants for specialty clinics). FOR FURTHER INFORMATION: DEPARTMENT OF HEALTH AND HUMAN SERVICES As required by the Privacy Act of 1974, as amended, 5 U.S.C. 552a(e)(4), this document sets forth the amendment of the proposed alteration of a system of records maintained by the IHS, following the initial publication in the Federal Register at 71 FR 16320 on March 31, 2006. The purpose of altering System No. 09–17–0003, ‘‘Medical Staff Credentials and Privileges Records,’’ is to enable IHS to reflect current program changes, technology changes, statutory and implementation changes. During the comment period, IHS received no comments from the public. The revision or modification of the IHS addresses in Appendix 1 is necessary to this system of records as administrative changes. In Appendix 1, the address for the Elko Service Unit, Newe Medical Clinic under the Phoenix Area IHS was removed as this facility is no longer under the control of the IHS. This Notice meets the requirement to notify the public that the IHS is amending the proposed changes in the IHS system of records by incorporating the administratie change following the initial publication at 71 FR 16320, March 31, 2006. With this notification, this system of records is effective June 15, 2006. Indian Health Service DEPARTMENT OF HEALTH AND HUMAN SERVICES VI. Electronic Access Copies of the guidance document entitled ‘‘Specifications: Test Procedures and Acceptance Criteria for New Veterinary Drug Substances and New Medicinal Products: Chemical Substances (VICH GL–39) may be obtained on the Internet from the CVM home page at https://www.fda.gov/cvm. Dated: June 6, 2006. Jeffrey Shuren, Assistant Commissioner for Policy. [FR Doc. E6–9327 Filed 6–14–06; 8:45 am] BILLING CODE 4160–01–S Privacy Act System of Records— Medical Staff Credentials and Privileges Records AGENCY: 09–17–0003 SYSTEM NAME: Indian Health Service Medical Staff Credentials and Privileges Records, HHS/IHS/OCPS. Indian Health Service (IHS), HHS. Amendment of one altered Privacy Act system of records. jlentini on PROD1PC65 with NOTICES ACTION: SECURITY CLASSIFICATION: SUMMARY: Pursuant to the provisions of the Privacy Act of 1974, as amended, 5 U.S.C. 552a(e)(4), the IHS has amended and is publishing the proposed alteration of a system of records, System No. 09–17–0003, ‘‘Medical Staff Credentials and Privileges Records.’’ The amended and altered system of records makes only one administrative revision as necessary. DATES: The amended and altered system, which incorporates no public comments received following the initial VerDate Aug<31>2005 15:47 Jun 14, 2006 Jkt 208001 SUPPLEMENTARY INFORMATION: None. SYSTEM LOCATION: Each Indian Health Service (IHS) Area Office and each IHS Service Unit (Appendix 1). Records may also be located at hospitals and offices of health care providers who are under contract with IHS. A current list of contractor sites is available by writing to the appropriate System Manager (Area or Service Unit Director) at the address shown in Appendix I. PO 00000 Frm 00038 Fmt 4703 Sfmt 4703 CATEGORIES OF RECORDS IN THE SYSTEM: Contains name, Social Security number, IHS medical staff membership and privileges applications and associated forms, employment data, liability insurance coverage, credentialing history of licensed health professionals, personal, educational, and demographic background information, professional performance information consisting of continuing education, performance awards, and adverse or disciplinary actions, and evaluations and approvals completed by IHS medical staff reviewers. AUTHORITY FOR MAINTENANCE OF THE SYSTEM: Federal Records Act (44 U.S.C. 2901), Privacy Act of 1974, as amended (5 U.S.C. 552a), Indian Self Determination and Education and Assistance Act (25 U.S.C. 450), Snyder Act (25 U.S.C. 13), Indian Health Care Improvement Act (25 U.S.C. 1601 et seq.), Indian Health E:\FR\FM\15JNN1.SGM 15JNN1

Agencies

[Federal Register Volume 71, Number 115 (Thursday, June 15, 2006)]
[Notices]
[Pages 34625-34626]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: E6-9327]



[[Page 34625]]

-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. 2005D-0199]


International Cooperation on Harmonisation of Technical 
Requirements for Registration of Veterinary Medicinal Products; Final 
Guidance for Industry on ``Specifications: Test Procedures and 
Acceptance Criteria for New Veterinary Drug Substances and New 
Medicinal Products: Chemical Substances;'' Availability

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice of availability.

-----------------------------------------------------------------------

SUMMARY: The Food and Drug Administration (FDA) is announcing the 
availability of a guidance document for industry (176) 
entitled ``Specifications: Test Procedures and Acceptance Criteria for 
New Veterinary Drug Substances and New Medicinal Products: Chemical 
Substances'' (VICH GL-39). This guidance has been developed for 
veterinary use by the International Cooperation on Harmonization of 
Technical Requirements for Registration of Veterinary Medicinal 
Products (VICH). This VICH guidance document is intended to assist to 
the extent possible, in the establishment of a single set of 
recommended global specifications for new veterinary drug substances 
and medicinal products. It provides guidance through recommendations on 
the setting and justification of acceptance criteria and the selection 
of test procedures for new veterinary drug substances of synthetic 
chemical origin, and new medicinal products produced from them, which 
have not been registered previously in the United States, the European 
Union, or Japan.

DATES: Submit written or electronic comments at any time.

ADDRESSES: Submit written requests for single copies of the guidance to 
the Communications Staff (HFV-12), Center for Veterinary Medicine 
(CVM), Food and Drug Administration, 7519 Standish Pl., Rockville, MD 
20855. Send one self-addressed adhesive label to assist that office in 
processing your requests. See the SUPPLEMENTARY INFORMATION section for 
electronic access to the guidance document.
    Submit written comments on the guidance to the Division of Dockets 
Management (HFA-305), Food and Drug Administration, 5630 Fishers Lane, 
rm. 1061, Rockville, MD 20852. Submit electronic comments to https://
www.fda.gov/dockets/ecomments. Comments should be identified with the 
full title of the guidance and the docket number found in brackets in 
the heading of this document.

FOR FURTHER INFORMATION CONTACT: Dennis Bensley, Center for Veterinary 
Medicine (HFV-143), Food and Drug Administration, 7500 Standish Pl., 
Rockville, MD 20855, 301-827-6956, e-mail: dennis.bensley@fda.hhs.gov.

SUPPLEMENTARY INFORMATION:

I. Background

    In recent years, many important initiatives have been undertaken by 
regulatory authorities and industry associations to promote the 
international harmonization of regulatory requirements. FDA has 
participated in efforts to enhance harmonization and has expressed its 
commitment to seek scientifically based harmonized technical procedures 
for the development of pharmaceutical products. One of the goals of 
harmonization is to identify and then reduce differences in technical 
requirements for drug development among regulatory agencies in 
different countries.
    FDA has actively participated in the International Conference on 
Harmonization of Technical Requirements for Approval of Pharmaceuticals 
for Human Use for several years to develop harmonized technical 
requirements for the approval of human pharmaceutical and biological 
products among the European Union, Japan, and the United States. The 
VICH is a parallel initiative for veterinary medicinal products. The 
VICH is concerned with developing harmonized technical requirements for 
the approval of veterinary medicinal products in the European Union, 
Japan, and the United States, and includes input from both regulatory 
and industry representatives.
    The VICH Steering Committee is composed of member representatives 
from the European Commission, European Medicines Evaluation Agency, 
European Federation of Animal Health, Committee on Veterinary Medicinal 
Products, the U.S. FDA, the U.S. Department of Agriculture, the Animal 
Health Institute, the Japanese Veterinary Pharmaceutical Association, 
the Japanese Association of Veterinary Biologics, and the Japanese 
Ministry of Agriculture, Forestry and Fisheries.
    Four observers are eligible to participate in the VICH Steering 
Committee: One representative from the government of Australia/New 
Zealand, one representative from the industry in Australia/New Zealand, 
one representative from the government of Canada, and one 
representative from the industry of Canada. The VICH Secretariat, which 
coordinates the preparation of documentation, is provided by the 
International Federation for Animal Health (IFAH). An IFAH 
representative also participates in the VICH Steering Committee 
meetings.

II. Guidance on Chemical Substance

    In the Federal Register of May 27, 2005 (70 FR 30761), FDA 
published the notice of availability of the VICH draft guidance, giving 
interested persons until June 27, 2005, to submit comments. No comments 
were received. At a meeting held on November 2005, the VICH Steering 
Committee endorsed the final guidance for industry, (VICH GL-39). This 
VICH guidance addresses specifications, i.e., those tests, procedures, 
and acceptance criteria which play a major role in assuring the quality 
of the new veterinary drug substance and medicinal product at release 
and during shelf life.

III. Paperwork Reduction Act of 1995

    This guidance document refers to previously approved collections of 
information found in FDA regulations. These collections of information 
are subject to review by the Office of Management and Budget (OMB) 
under the Paperwork Reduction Act of 1995 (44 U.S.C. 3501-3520). The 
collections of information in 21 CFR 514.1 have been approved under OMB 
Control No. 0910-0032 (expiration date 12/31/2007).

IV. Significance of Guidance

    This document, developed under the VICH process, has been revised 
to conform to FDA's good guidance practices regulation (21 CFR 10.115). 
For example, the document has been designated ``guidance'' rather than 
``guideline.'' In addition, guidance documents must not include 
mandatory language such as ``shall,'' ``must,'' ``require,'' or 
``requirement,'' unless FDA is using these words to describe a 
statutory or regulatory requirement.
    The VICH guidance (176) is consistent with the agency's 
current thinking on the new veterinary drug substances and medicinal 
products. This guidance does not create or confer any rights for or on 
any person and will not operate to bind FDA or the public. An 
alternative method may be used as long as it satisfies the requirements 
of applicable statutes and regulations.

[[Page 34626]]

V. Comments

    As with all of FDA's guidances, the public is encouraged to submit 
written or electronic comments pertinent to this guidance. FDA will 
periodically review the comments in the docket and, where appropriate, 
will amend the guidance. The agency will notify the public of any such 
amendments through a notice in the Federal Register.
    Interested persons may submit to the Division of Dockets Management 
(see ADDRESSES) written or electronic comments regarding this document. 
Submit a single copy of electronic comments or two paper copies of any 
mailed comments, except that individuals may submit one paper copy. 
Comments are to be identified with the docket number found in brackets 
in the heading of this document. Received comments may be seen in the 
Division of Dockets Management between 9 a.m. and 4 p.m., Monday 
through Friday

VI. Electronic Access

    Copies of the guidance document entitled ``Specifications: Test 
Procedures and Acceptance Criteria for New Veterinary Drug Substances 
and New Medicinal Products: Chemical Substances (VICH GL-39) may be 
obtained on the Internet from the CVM home page at https://www.fda.gov/
cvm.

    Dated: June 6, 2006.
Jeffrey Shuren,
Assistant Commissioner for Policy.
[FR Doc. E6-9327 Filed 6-14-06; 8:45 am]
BILLING CODE 4160-01-S

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.